Pioglitazone Hydrochloride (Actos(Registered Trademark)) to Treat Asthma
|ClinicalTrials.gov Identifier: NCT00604578|
Recruitment Status : Withdrawn
First Posted : January 30, 2008
Last Update Posted : July 2, 2017
This study will test whether pioglitazone hydrochloride (Actos (Registered Trademark) Registered Trademark) is effective for treating patients with asthma who do not respond to standard therapy. Experiments have shown that this drug, which is used to treat patients with diabetes, may be effective for treating asthma.
People between 18 and 75 years of age who have had asthma for at least a1 year and whose symptoms are not well controlled with high doses of inhaled corticosteroids with or without long-acting bronchodilators may be eligible for this study. Candidates are screened with breathing tests, an allergy skin test, chest x-ray, electrocardiogram (ECG), echocardiogram (ultrasound test of the heart), blood tests, and DEXA scan (an x-ray to measure bone thickness) to make sure they are eligible for the study.
Then, participants undergo tests and procedures in the following study phases:
Participants are given a device to measure and record their lung function and asthma symptoms at home each morning and night for 4 weeks before starting the study medication. Lung function is also measured at clinic visits before and after inhaling a bronchodilator medicine. Before starting the study medication, participants have a sputum induction (sputum collection test). For this test, the participants inhale a salt-water mist and are asked to collect sputum into a plastic cup.
Participants are randomly selected to receive either pioglitazone hydrochloride or placebo (a look-alike pill with no active ingredient) once a day for 10 weeks. They return to the clinic after 2 weeks to repeat the tests done in Phase 1 and to monitor any reactions to the study drug or placebo. If there are no problems, the amount of medication is increased once, and then they return for follow-up evaluations every 2 weeks for 8 weeks. Pulmonary function tests, sputum collection and DEXA scan are repeated after 10 weeks on medication.
Patients return for follow-up 1 month after stopping the medication or placebo to monitor their asthma.
|Condition or disease||Intervention/treatment||Phase|
|Asthma Airway Inflammation Airflow Obstruction Airway Hyperactivity||Drug: Pioglitazone Hydrochloride||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Allergic Asthma|
|Study Start Date :||January 4, 2008|
|Estimated Primary Completion Date :||October 30, 2009|
|Estimated Study Completion Date :||October 30, 2009|
- The change in post-bronchodilator FEV1. [ Time Frame: 10 weeks ]
- Airway inflammation, Airflow Obstruction, Airway Hyperreactivity, Asthma Symptoms, Rate of mild exacerbation, Rate of severe exacerbation, Asthma Quality-of-life, Blood Eosinophil Counts, Serum IgE and Exhaled Nitric Oxide Levels. [ Time Frame: 10 weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00604578
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|United States, Virginia|
|Falls Church, Virginia, United States, 22046|